Solasia Pharma K.K. (TYO:4597)
Japan
· Delayed Price · Currency is JPY 31.00
-3.00 (-8.82%)
Mar 9, 2026, 3:30 PM JST
Solasia Pharma K.K. Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 429 | 316 | 617 | 1,092 | 559 | Upgrade
|
| Revenue Growth (YoY) | 35.76% | -48.78% | -43.50% | 95.35% | 23.13% | Upgrade
|
| Cost of Revenue | 221 | 131 | 280 | 430 | 185 | Upgrade
|
| Gross Profit | 208 | 185 | 337 | 662 | 374 | Upgrade
|
| Selling, General & Admin | 637 | 1,721 | 1,073 | 2,250 | 1,948 | Upgrade
|
| Research & Development | 430 | 414 | 403 | 883 | 845 | Upgrade
|
| Operating Expenses | 1,067 | 2,135 | 1,476 | 3,133 | 2,793 | Upgrade
|
| Operating Income | -859 | -1,950 | -1,139 | -2,471 | -2,419 | Upgrade
|
| Interest Expense | -14 | -5 | - | -18 | -23 | Upgrade
|
| Interest & Investment Income | 1 | - | 10 | - | - | Upgrade
|
| Earnings From Equity Investments | -1 | -4 | -5 | -3 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -3 | -1 | -1 | - | -1 | Upgrade
|
| Pretax Income | -876 | -1,960 | -1,135 | -2,492 | -2,443 | Upgrade
|
| Income Tax Expense | - | -19 | -23 | 56 | 35 | Upgrade
|
| Net Income | -876 | -1,941 | -1,112 | -2,548 | -2,478 | Upgrade
|
| Net Income to Common | -876 | -1,941 | -1,112 | -2,548 | -2,478 | Upgrade
|
| Shares Outstanding (Basic) | 238 | 199 | 168 | 152 | 130 | Upgrade
|
| Shares Outstanding (Diluted) | 238 | 199 | 168 | 152 | 130 | Upgrade
|
| Shares Change (YoY) | 19.53% | 18.18% | 10.62% | 16.78% | 10.88% | Upgrade
|
| EPS (Basic) | -3.69 | -9.77 | -6.61 | -16.76 | -19.04 | Upgrade
|
| EPS (Diluted) | -3.69 | -9.77 | -6.62 | -16.77 | -19.04 | Upgrade
|
| Free Cash Flow | -847 | -1,034 | -359 | -2,074 | -2,475 | Upgrade
|
| Free Cash Flow Per Share | -3.57 | -5.20 | -2.13 | -13.65 | -19.02 | Upgrade
|
| Gross Margin | 48.48% | 58.54% | 54.62% | 60.62% | 66.91% | Upgrade
|
| Operating Margin | -200.23% | -617.09% | -184.60% | -226.28% | -432.74% | Upgrade
|
| Profit Margin | -204.20% | -614.24% | -180.23% | -233.33% | -443.29% | Upgrade
|
| Free Cash Flow Margin | -197.44% | -327.21% | -58.18% | -189.93% | -442.75% | Upgrade
|
| EBITDA | -822 | -1,755 | -639 | -1,937 | -1,924 | Upgrade
|
| EBITDA Margin | -191.61% | - | -103.57% | -177.38% | - | Upgrade
|
| D&A For EBITDA | 37 | 195 | 500 | 534 | 495 | Upgrade
|
| EBIT | -859 | -1,950 | -1,139 | -2,471 | -2,419 | Upgrade
|
| EBIT Margin | -200.23% | - | -184.60% | -226.28% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.